Search results for "Rectal Cancer"

showing 10 items of 978 documents

CD9a expression in premalignant lesions, gastric and colorectal carcinoma

2017

Oncologymedicine.medical_specialtybusiness.industryColorectal cancerInternal medicinemedicinebusinessmedicine.diseasePathology and Forensic MedicinePathology
researchProduct

A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer

2019

Oncologymedicine.medical_specialtybusiness.industryColorectal cancermedicine.medical_treatmentHematologymedicine.diseaseWNT5AOncologyInternal medicineMedicineIn patientOpen labelbusinessNeoadjuvant therapyWnt 5a proteinAnnals of Oncology
researchProduct

Risk Factors for Urinary Dysfunction after Rectal Cancer Surgery

2014

Oncologymedicine.medical_specialtybusiness.industryInternal medicineUrinary systemRectal cancer surgeryUrologyMedicineSurgerybusinessJournal of the American College of Surgeons
researchProduct

<i>BRAF</i> Mutation Testing in Lynch Syndrome Diagnostics: Performance and Efficiency According to Patient's Age

2019

Background: BRAF V600E mutations are reportedly associated with sporadic microsatellite-unstable (MSI) colorectal cancer (CRC), while rarely detected in CRCs of Lynch syndrome (LS) patients. Therefore, current international diagnostic guidelines recommend somatic BRAF mutation testing in MLH1-deficient MSI CRC patients to exclude LS. As sporadic BRAF- mutant MSI CRC is a disease of the elderly, while LS-associated CRC usually occurs at younger age, we hypothesized that the efficacy of BRAF testing in LS diagnostics may be age-dependent. Methods: We systematically compared the prevalence of BRAF mutations in LS-associated CRCs and MSI CRCs from population-based cohorts in different age group…

Oncologymedicine.medical_specialtyeducation.field_of_studyColorectal cancerbusiness.industryGenetic counselingPopulationCancerMicrosatellite instabilityDiseasemedicine.diseasedigestive system diseasesLynch syndromeInternal medicinemedicineMutation testingeducationbusinessneoplasmsSSRN Electronic Journal
researchProduct

Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients

2004

Aims. The pharmacokinetics of 5-fluorouracil (5-FU) after intravenous administration in color- ectal cancer patients were examined using population analysis. The relevant covariates and the extent of inter- and intraindividual variability were evaluated. Methods. Data from 27 patients with diagnosis of nonmetastatic colorectal adenocarcinoma receiving weekly 5-FU (450 mg/m2), plus levamisol 50 mg/8 hours by oral route for 3 days every 15 days, were pooled with data from 17 patients with diagnosis of metastatic colorectal adenocarcinoma, receiving daily 5-FU (425 mg/m2) and intravenous folinic acid (20 mg/m2) over five consecutive days (daily times five), every four weeks. In both groups 5-…

Oncologymedicine.medical_specialtyeducation.field_of_studyColorectal cancerbusiness.industryPopulationCancerPopulation pharmacokineticsmedicine.disease030226 pharmacology & pharmacyGastroenterology03 medical and health sciencesFolinic acid0302 clinical medicineOncologyPharmacokineticsFluorouracil030220 oncology & carcinogenesisInternal medicinemedicinePharmacology (medical)Every Four Weekseducationbusinessmedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population: Modulation by gender

2018

Oncologymedicine.medical_specialtyeducation.field_of_studyColorectal cancerbusiness.industryPopulationHematologymedicine.diseaseOncologyInternal medicinemedicineNod2 geneeducationbusinessAnnals of Oncology
researchProduct

Incidence and survival in late liver metastases of colorectal cancer

2014

Background and Aims Data concerning the risk of long-term liver metastasis following surgery of colorectal cancer in the general population are scarce. The 10-year incidence and prognosis of metachronous liver metastases remain unknown. Methods Among 4584 patients resected for cure for colorectal cancer recorded in two French digestive population-based cancer registries between 1985 and 2000, 602 presented metastases including liver metastases. Results The cumulated incidence of liver metastasis was 15% at 5 years and 17% at 10 years, and was mainly related to stage at diagnosis. The 10-year cumulative incidence was 6% for stage I and 30% for stage III. The hazard ratio was 3.2 [2.4–4.3] fo…

Oncologymedicine.medical_specialtyeducation.field_of_studyHepatologyRelative survivalbusiness.industryColorectal cancerPopulationHazard ratioGastroenterologyCancermedicine.diseaseCancer registryMetastasisInternal medicineMedicineCumulative incidencebusinesseducationJournal of Gastroenterology and Hepatology
researchProduct

Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators

2014

ABSTRACT Aim: The MOSAIC study (Andre T, N Engl J Med, 2004) has demonstrated in patients with stage II/III resected colon cancer (CC) a benefit of oxaliplatin added to 5FU and LV (LV5FU) in 3-year disease-free survival (DFS) and in overal survival (OS). LV5FU and oxaliplatin (FOLFOX4) has also shown a benefit in deficient MisMatch Repair (dMMR) CC pts (Flejou JF, J Clin Oncol 31: 2013;suppl; abstr 3524). We report here 1) Results of MOSAIC after 10 year follow-up, and 2) results in the BRAF evaluable population. Methods: Of the 2246 patients included in the MOSAIC study (whole population), the actualization of survival data was done with 10 yrs follow up. Formalin-fixed, paraffin-embedded …

Oncologymedicine.medical_specialtyeducation.field_of_studyMultivariate analysisbusiness.industryColorectal cancerPopulationHematologymedicine.diseaseOxaliplatinSurgeryOncologyInternal medicinemedicineAdjuvant therapyOverall survivalMutational statusStage (cooking)businesseducationneoplasmsmedicine.drugAnnals of Oncology
researchProduct

Hereditary ovarian cancer.

2008

Apoptosis is a form of cell death that permits the removal of damaged, senescent or unwanted cells in multicellular organisms, without damage to the cellular microenvironment. Defective apoptosis represents a major causative factor in the development and progression of cancer. The majority of chemotherapeutic agents, as well as radiation, utilize the apoptotic pathway to induce cancer cell death. Resistance to standard chemotherapeutic strategies also seems to be due to alterations in the apoptotic pathway of cancer cells. Recent knowledge on apoptosis has provided the basis for novel targeted therapies that exploit apoptosis to treat cancer. These new target include those acting in the ext…

Oncologymedicine.medical_specialtyendocrine system diseasesColorectal cancerMLH1Germline mutationNeoplastic Syndromes HereditaryInternal medicineGenetic predispositionMedicineHumansGenetic Predisposition to DiseaseGenetic testingOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryBRCA mutationHematologymedicine.diseasePrognosisfemale genital diseases and pregnancy complicationsovarian cancerOncologyMSH2FemalebusinessOvarian cancer
researchProduct

Rectal cancer: Assessment of response to neoadjuvant chemoradiation by dynamic contrast-enhanced MRI

2012

Purpose To assess pretreatment functional and morphological tumor characteristics with magnetic resonance imaging (MRI) in advanced rectal carcinoma and to identify factors predicting response to neoadjuvant chemoradiation. Materials and Methods In a prospective study, 95 patients with rectal carcinoma underwent dynamic contrast-enhanced MRI before and after chemoradiation. Quantitative parameters were derived from a pharmacokinetic two-compartment model. Tumors were also characterized with regard to mucinous status at pretreatment high-resolution MRI as nonmucinous or mucinous. Response to treatment was defined as a downshift in the local tumor stage. Results The parameter k21 (contrast me…

Oncologymedicine.medical_specialtymedicine.diagnostic_testColorectal cancerbusiness.industryMagnetic resonance imagingOdds ratiomedicine.diseaseContrast mediumInternal medicineDynamic contrast-enhanced MRImedicineMucinous carcinomaRadiology Nuclear Medicine and imagingMucinous TumorNuclear medicinebusinessProspective cohort studyJournal of Magnetic Resonance Imaging
researchProduct